The VISION trial investigated this approach by enrolling patients with metastatic castration-resistant prostate cancer who had previously received at least one androgen receptor pathway inhibitor and one or two taxane-based treatments, and who exhibited PSMA-positive [68Ga]Ga-PSMA-11 scans [69]. This evidence concerns the gene FOLH1 and prostate cancer.